Bristol-Myers Squibb Company (BMY)

FairStock Score: 71/100 — STEADY

Key Financials

Strengths

• Dominant oncology portfolio with Opdivo generating sustained revenues across multiple indications
• Strong free cash flow generation of $11.1B annually provides financial flexibility
• Exceptional ROE of 40.4% demonstrates operational efficiency in drug development and manufacturing
• Low beta of 0.27 indicates defensive characteristics during market volatility
• Diversified therapeutic areas reduce single-product dependency risk

Concerns

• Extreme valuation disconnect—EV/EBITDA of 55.47x and Graham Number analysis suggests 479% overvaluation
• Deteriorating financial quality evidenced by Piotroski F-Score of only 6/9
• High leverage with D/E ratio of 2.55 creates vulnerability to patent cliff events and regulatory setbacks
• Altman Z-Score of 1.61 indicates financial distress warning zone, unusual for a cash-generative pharma giant

AI Analysis

Bristol-Myers Squibb presents a classic pharmaceutical conundrum—a business with genuine competitive moats in oncology and immunology, yet priced for perfection. At 16.6x earnings with an EV/EBITDA of 55.47x, the market is assigning extraordinary growth expectations to a mature, cash-generative enterprise. Let me be direct: the fundamentals are sound but not compelling at this valuation. The company generates exceptional free cash flow of $11.1B annually—a 1.3% yield on market cap—which signals operational competence. The portfolio anchored by Opdivo and Orencia represents genuine competitive advantages in difficult-to-treat diseases. The 40% ROE is impressive, though one must remember pharmaceutical ROEs are often inflated by intangible asset accounting. However, I'm troubled by several realities. The Altman Z-score of 1.61 sits uncomfortably close to distress territory, while a debt-to-equity ratio of 2.55 reveals financial leverage that concerns me in a sector dependent on patent cliffs and regulatory caprice. The Graham Number suggests fair value near $10.40—a stark 479% margin of safety gap that screams overvaluation by fundamental measures. The Piotroski score of 6/9 indicates deteriorating financial quality, and at age 122 (market cap in billions), BMY is no longer a growth story. Pipeline strength matters, but it's already reflected in these prices. I demand a margin of safety. At $60, Bristol-Myers offers neither the growth of a compounder nor the yield of a stable business. I'd revisit this at $45 or below.

Bull Case

BMY's dominant oncology franchise continues generating reliable cash flows while pipeline advances in immunotherapy could accelerate growth. At just 16.6x earnings with $11B annual FCF, a disciplined investor gains exposure to recession-resistant healthcare innovation with potential 20-25% upside if new approvals accelerate revenue growth.

Bear Case

Patent cliffs on key franchises, combined with 2.55x leverage and weakening financial metrics, position BMY poorly for setbacks. If pipeline underperforms or major drugs face generic competition earlier than expected, the 55x EV/EBITDA multiple collapses, erasing 40-50% of shareholder value.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer